Lack of proper tools hampers early diagnosis and treatment of antigen-specific autoimmune diseases. A new strategy that makes use of peptide-MHC reagents could control recent-onset diabetes in mice.
This is a preview of subscription content, log in via an institution to check access.
Bob Crimi
References
Casares, S. et al. Nature Immunol., 3, 385–393 (2002).
Sharma, S. D. et al. Proc. Natl Acad. Sci. USA 88, 11465–11469 (1991).
Spack, E. G. et al. J. Autoimmun. 8, 787–807 (1995).
Amrani, A. et al. Nature 406, 739–742 (2000).
Yu, L. et al. Proc. Natl Acad. Sci. USA 97, 1701–1706 (2000).
Daniel, D. et al. Eur. J. Immunol. 25, 1056–1062 (1995).
Lee, K. H. et al. Nature Immunology 2, 501–507 (2001).
Abiru, N. et al. Diabetes 50, 1274–1281 (2001).
Novak, E. J. et al. J. Clin. Invest. 104, R63–R67 (1999).
Kwok, W. W. et al. J. Immunol. 164, 4244–4249 (2000).
Meyer, A. L. et al. Proc. Natl Acad. Sci. USA 97, 11433–11438 (2000).
Quarsten, H. et al. 167, 4861–4868 (2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eisenbarth, G., Nepom, G. Class II peptide multimers: promise for type 1A diabetes?. Nat Immunol 3, 344–345 (2002). https://doi.org/10.1038/ni0402-344
Issue Date:
DOI: https://doi.org/10.1038/ni0402-344
- Springer Nature America, Inc.